Classification of type 2 diabetes by clinical response to metformin-troglitazone combination and C-Peptide criteria.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
A Lee, J E Morley

Abstract

To assess the ability of basal and stimulated C-peptide levels and stimulated glucose values after oral administration of glucose to predict a successful response to metformin and troglitazone combination therapy after discontinuation of insulin therapy. At the onset of the study, plasma glucose and C-peptide levels were measured in a group of 64 obese patients with insulin-treated type 2 diabetes while they were fasting and 2 hours after a challenge of 100 g of glucose administered orally. Then combination metformin-troglitazone treatment was initiated while insulin therapy was gradually tapered over 8 to 12 weeks. Subjects who successfully tolerated insulin withdrawal after the metformin-troglitazone combination were categorized as non-insulin-requiring responders, whereas those who needed insulin to obtain glycemic control were categorized as insulin-requiring nonresponders. Basal and glucose-stimulated C-peptide levels as well as stimulated glucose values were contrasted in the responder versus nonresponder groups. In a second protocol, eight obese patients with insulin-treated type 2 diabetes who successfully stopped insulin therapy were reassessed for C-peptide and glucose variables during the 2-hour oral glucose toleranc...Continue Reading

References

Jun 1, 1992·Diabetes Care·C J Bailey
Dec 1, 1990·Diabetes Care·S Genuth
Nov 2, 1989·The New England Journal of Medicine·J E Gerich
Nov 3, 1994·The New England Journal of Medicine·J J NolanJ Olefsky
Jan 1, 1996·Annals of Internal Medicine·M I Harris
Oct 6, 1997·Endocrinology and Metabolism Clinics of North America·M C Riddle
Mar 27, 1998·The New England Journal of Medicine·S E InzucchiG I Shulman
May 1, 1996·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·A LeeJ E Morley
Jul 15, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·C A StuartR F Carlson

❮ Previous
Next ❯

Citations

Aug 17, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·A G JonesA T Hattersley
Feb 19, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·A G Jones, A T Hattersley
Aug 11, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·D KumarS Madha
Sep 14, 2000·Clinics in Geriatric Medicine·A Lee

❮ Previous
Next ❯

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
A LeeJ E Morley
Diabetic Medicine : a Journal of the British Diabetic Association
P J GrantD W Miles
© 2022 Meta ULC. All rights reserved